As the U.S. stock market shows signs of strength with major indices on track for weekly and monthly gains, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, though often overlooked due to their historical connotations, represent an intriguing segment of the market by highlighting smaller or less-established companies that can offer substantial value. By focusing on those with robust financials and clear growth potential, investors may uncover promising opportunities within this category.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Dingdong (Cayman) (DDL) | $1.82 | $400.75M | ✅ 4 ⚠️ 0 View Analysis > |
| Waterdrop (WDH) | $1.74 | $622.06M | ✅ 4 ⚠️ 0 View Analysis > |
| WM Technology (MAPS) | $1.02 | $181.28M | ✅ 4 ⚠️ 2 View Analysis > |
| LexinFintech Holdings (LX) | $3.85 | $620.89M | ✅ 4 ⚠️ 1 View Analysis > |
| Global Self Storage (SELF) | $4.97 | $55.95M | ✅ 5 ⚠️ 1 View Analysis > |
| Sensus Healthcare (SRTS) | $3.18 | $52.77M | ✅ 4 ⚠️ 2 View Analysis > |
| Performance Shipping (PSHG) | $2.00 | $24.99M | ✅ 4 ⚠️ 2 View Analysis > |
| Golden Growers Cooperative (GGRO.U) | $5.00 | $77.45M | ✅ 2 ⚠️ 5 View Analysis > |
| BAB (BABB) | $0.9999 | $7.19M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $3.40 | $81.57M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 362 stocks from our US Penny Stocks screener.
Let's uncover some gems from our specialized screener.
AC Immune (ACIU)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: AC Immune SA is a clinical stage biopharmaceutical company focused on discovering, designing, and developing medicines and diagnostic products for neurodegenerative diseases related to protein misfolding, with a market cap of $379.94 million.
Operations: The company generates revenue of CHF 28.92 million from its segment focused on the discovery and development of therapeutic and diagnostic products.
Market Cap: $379.94M
AC Immune, a clinical-stage biopharmaceutical company, is navigating the penny stock landscape with strategic initiatives and promising research. Despite being unprofitable, it has reduced losses over the past five years by 3.5% annually and maintains a robust cash position with CHF 131.8 million in short-term assets exceeding liabilities. Recent developments include appointing Prof. Catherine Mummery to enhance its Clinical Advisory Board expertise and publishing positive Phase 1b/2a trial results for ACI-35.030, an active immunotherapy targeting Tau proteins in Alzheimer's disease. The company is focused on key assets while reducing its workforce by 30%, extending operational cash through Q3 2027.
- Take a closer look at AC Immune's potential here in our financial health report.
- Explore AC Immune's analyst forecasts in our growth report.
Adagene (ADAG)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Adagene Inc. is a clinical stage biotechnology company focused on the research, development, and production of monoclonal antibody drugs for cancer treatment in China, with a market cap of $86.72 million.
Operations: Adagene Inc. has not reported any specific revenue segments.
Market Cap: $86.72M
Adagene Inc., a clinical-stage biotechnology firm, is navigating the penny stock arena with its focus on monoclonal antibody drugs for cancer treatment. Despite being pre-revenue, it has managed to reduce losses by 11.8% annually over five years and maintains a stable cash runway exceeding one year. The company's short-term assets of US$65.4 million comfortably cover both short and long-term liabilities, while its debt level remains manageable with more cash than total debt. Recent developments include an amended collaboration with Exelixis to utilize Adagene's SAFEbody technology, potentially unlocking future milestone payments and royalties.
- Click to explore a detailed breakdown of our findings in Adagene's financial health report.
- Review our growth performance report to gain insights into Adagene's future.
Butler National (BUKS)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Butler National Corporation specializes in the design, engineering, manufacturing, and servicing of aerostructures and aircraft components with a market cap of $166.23 million.
Operations: The company's revenue is primarily derived from its Gaming segment at $37.84 million, followed by Aircraft Modifications at $28.12 million, Special Mission Electronics at $13.95 million, and Aircraft Avionics contributing $4.35 million.
Market Cap: $166.23M
Butler National Corporation, with a market cap of US$166.23 million, is an intriguing penny stock due to its diversified revenue streams, primarily from Gaming and Aircraft Modifications. Recent earnings for Q1 2025 showed increased revenue of US$20.13 million and net income growth to US$3.69 million year-over-year. The company's financial health is supported by short-term assets exceeding liabilities and satisfactory debt levels, with interest payments well-covered by EBIT. Despite a high return on equity at 21.4%, challenges include negative earnings growth in the past year and an inexperienced management team averaging less than one year in tenure.
- Click here and access our complete financial health analysis report to understand the dynamics of Butler National.
- Examine Butler National's past performance report to understand how it has performed in prior years.
Taking Advantage
- Take a closer look at our US Penny Stocks list of 362 companies by clicking here.
- Seeking Other Investments? Outshine the giants: these 26 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if AC Immune might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com